SCHEMBL6090949

SCHEMBL6090949

OC(c1ccccc1)(c1ncc[nH]1)c1ncc[nH]1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 4/20 0.64
MTOR P42345 1/20 0.42
ADK P55263 1/20 0.42
NISCH Q9Y2I1 1/20 0.42
KMT2A Q03164 2/20 0.42
CFTR P13569 1/20 0.42
GOPC Q9HD26 1/20 0.42
TAAR1 Q96RJ0 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CSNK1A1 P48729 1/20 0.33
TYRO3 Q06418 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
ADRA1A P35348 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11537316 0.87 CYP19A1 (0.62) CYP19A1MTORADKNISCHKMT2A
SCHEMBL11535325 0.87 CYP19A1 (0.62) CYP19A1MTORADKNISCHKMT2A
SCHEMBL11532100 0.87 CYP19A1 (0.62) CYP19A1MTORADKNISCHKMT2A
SCHEMBL11534840 0.87 CYP19A1 (0.88) CYP19A1CYP3A4
SCHEMBL11533232 0.87 CYP19A1 (0.62) CYP19A1MTORADKNISCHKMT2A
SCHEMBL11533069 0.84 CYP19A1 (0.59) CYP19A1MTORADKNISCHKMT2A
SCHEMBL11535538 0.84 CYP19A1 (0.51) CYP19A1MTORADKNISCHKMT2A
SCHEMBL11533065 0.83 CYP19A1 (0.66) CYP19A1TAAR1
SCHEMBL11536872 0.83 CYP19A1 (0.54) CYP19A1KMT2ATAAR1CYP3A4TSHR
SCHEMBL17263156 0.82 CYP19A1 (0.49) CYP19A1MTORADKNISCHKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211759-A1 Bis-heterocyclic compounds with antitumour and chemosensitising activity SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2006-09-21 US disclosed
EP-1337511-A1 BIS-HETEROCYCLIC COMPOUNDS WITH ANTITUMOUR AND CHEMOSENSITISING ACTIVITY Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 2003-08-27 EP disclosed
WO-2002036561-A1 BIS-HETEROCYCLIC COMPOUNDS WITH ANTITUMOUR AND CHEMOSENSITISING ACTIVITY SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2002-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211759-A1 Bis-heterocyclic compounds with antitumour and chemosensitising activity ABCC1, MCL1, DPYD CYP19A1 1156/4885MTOR 2203/4885ADK 3366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.